NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT05633602 2025-05-28
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
Phase 3 Active not recruiting
NCT01168973 2019-09-25
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
Eli Lilly and Company
Phase 3 Completed